Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Equity (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Return on Equity for 5 consecutive years, with 0.06% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 98.0% year-over-year to 0.06%, compared with a TTM value of 0.06% through Dec 2025, up 98.0%, and an annual FY2025 reading of 0.54%, up 47.0% over the prior year.
  • Return on Equity was 0.06% for Q4 2025 at SAB Biotherapeutics, up from 0.22% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.06% in Q4 2025 and bottomed at 1.8% in Q2 2025.
  • Average Return on Equity over 5 years is 0.82%, with a median of 0.77% recorded in 2024.
  • Peak annual rise in Return on Equity hit 98bps in 2025, while the deepest fall reached -98bps in 2025.
  • Year by year, Return on Equity stood at 0.47% in 2021, then plummeted by -30bps to 0.61% in 2022, then plummeted by -92bps to 1.16% in 2023, then rose by 11bps to 1.04% in 2024, then skyrocketed by 94bps to 0.06% in 2025.
  • Business Quant data shows Return on Equity for SABS at 0.06% in Q4 2025, 0.22% in Q3 2025, and 1.8% in Q2 2025.